Androgen Replacement Therapy Market, By Product Type (Testosterone Creams/Gels, Testosterone Patches, Testosterone Injections, Testosterone Implants, and Testosterone Tablets/Capsules/Gums), By Active Ingredient (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and Testosterone Cypionate), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023

Code : CMI3787

Pages :191

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints

The growth of the androgen replacement therapy market may be hampered, owing to the increasing product recalls of testosterone products in the market. For instance, in July 2022, the U.S. Food and Drug Administration (USFDA) enforced the recall of 50,680 vials of Testosterone Cypionate Injection, used to treat low testosterone in adult males produced by Sun Pharmaceutical Industries Ltd., a multinational pharmaceutical company headquartered in Mumbai, India.

This restrain can be overcome by strict compliance with the regulatory guidelines and introduction of Good Manufacturing Practices (GMP) in production.

Risk of prostate cancer

The side-effects associated with androgen replacement therapy are restraining the growth of this market. For instance, according the data shared by researchers at the Central European University, a private research university, in June 2022, there is a positive associations between high levels of free testosterone and increased risks of prostate cancer.

This can be overcome by taking proper dosages of testosterone which would not be toxic to the human system.

Global Androgen Replacement Therapy Market– Drivers

The increasing prevalence of hypogonadism

The growing prevalence of hypogonadism in adult men worldwide is major factor leading to the high demand growth of androgen replacement therapy market. For instance, according to the data published in January 2021, in PubMed, a free search engine for biological databases and medical reports, the estimated prevalence of hypogonadism varies between 2.1% and 38.7% in middle-aged and older men, but can increase to approximately 50% among individuals with diabetes or obesity globally.